PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2129051
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2129051
Apheresis market size was valued at US$ 3,180.6 Million in 2025, expanding at a CAGR of 8.2% from 2026 to 2033.
Apheresis is a procedure in which whole blood is withdrawn from a donor or patient and fractionated to separate the components. After separating the blood, the certain components of the body fluid of the patient are collected. The remaining components of the body fluid of the patient are then returned back to the body of the patient in their blood. This is a very commonly used technique in the extraction of different components of the blood from the body of the donor. This treatment technique is also used in the treatment of autoimmune disorders, neurological disorders, and cancerous disorders. Hence, apheresis treatment plays a key role in the specific collection of blood parts & disease cures.
Apheresis Market- Market Dynamics
Increasing Prevalence of Haematological Disorders to Fuel Market Demand
The increasing prevalence of haematological disorders is driving demand for the Apheresis market, with higher numbers of multiple myeloma, leukaemia, lymphoma and other forms of blood diseases requiring stem cell harvest and leukapheresis. For instance, in April 2026, according to Blood Cancer UK (Org.), the number of people who have been diagnosed with blood cancer in the UK is above 40,000 every year. About 310,000 people currently have blood cancer in the UK. Besides, there is a high probability that out of every 19 people in the UK, one may get blood cancer in his/her lifetime. This rising disease burden is expected to accelerate demand for apheresis procedures and related technologies.
The Global Apheresis market is segmented on the basis of Product, Type, Procedure, Technology, End User, and Region.
By procedure, plasmapheresis holds the major share in the global Apheresis market because of its increasing usage for the purpose of plasma donation and therapeutic plasma exchange procedures in case of neurological diseases, as well as autoimmune and haematologic disorders. The rise in applications of plasma, in terms of the development of treatments through the use of plasma, has led to increased demand for it. In June 2026, Haemonetics Corporation changed its structure of reporting and created the Apheresis segment, which includes the plasma and blood centre operations of the company. These factors are expected to strengthen plasmapheresis adoption and support sustained market growth during the forecast period.
Apheresis Market- Geographical Insights
The North American market maintained its key position, driven by the rising prevalence of chronic conditions such as autoimmune and neurological disorders, an increase in the number of apheresis procedures, a favourable reimbursement environment, and the presence of advanced healthcare infrastructure. For example, in November 2025, as per the reports from the Institute for Health Metrics and Evaluation (Org.) and the American Academy of Neurology, neurological disorders were found in 180.3 million patients, representing around 54% of the total population of the U.S. Moreover, neurological disorders were the major cause of disabilities in the U.S. Based on the research regarding the growing incidence of brain and nervous system disorders, it was found that 121.9 million people were suffering from tension-type headache, while many others were suffering from migraine and diabetic neuropathy (17.1 million). The increasing disease burden is likely to drive the demand for apheresis procedures in North America.
Japan Apheresis market - Country Insights
Japan's market is supported by a relatively high burden of chronic diseases and the growth in medical technologies, which in turn will create the demand for innovation. For instance, in November 2025, according to the U.S. International Trade Administration, the value of the medical devices market in Japan will be $34,240 million (USD), as compared to $32,609 million. The medical devices market will grow at a CAGR of 4.4% in 2029 due to the increasing number of aged people in Japan, as well as the requirement for medical devices like minimally invasive devices, diagnostic devices based on IoT and AI, telemedicine, self-care, and preventive devices. These trends are expected to strengthen Japan's demand for advanced, technology-driven healthcare solutions.
The global market for apheresis is becoming more competitive, and Fresenius SE & Co. KGaA, Haemonetics Corporation, Asahi Kasei Medical Co., Ltd, Terumo BCT, Inc., and Baxter International Inc. have been present in the market because of technological innovations, partnerships, acquisitions and mergers, and geographic expansion in response to the growing needs of the healthcare industry. In April 2025, Asahi Kasei Medical established itself as a new entity concentrating on medical devices by transferring 80% of its shares to Asahi Kasei Life Science but retaining its medical-device business, which included therapeutic apheresis. These strategic initiatives are expected to strengthen market positioning and drive innovation in therapeutic apheresis solutions.
In November 2025, Terumo Blood and Cell Technologies partnered with Santersus AG to merge Santersus' NucleoCapture(TM) blood purification technology with Terumo BCT's Spectra Optia(TM) Apheresis System and develop a revolutionary apheresis therapy for sepsis and other critical diseases.